JGC
TVTX icon

J. Goldman & Co’s Travere Therapeutics TVTX Stock Holding History

J. Goldman & Co’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-181,174
Closed -$3.16M – 648
2024
Q4 		$3.16M Buy
+181,174
New +$3.2M 0.08% 235
2023
Q4 		– Sell
-146,742
Closed -$1.31M – 478
2023
Q3 		$1.31M Buy
+146,742
New +$2.07M 0.05% 225
2019
Q3 		– Sell
-132,458
Closed -$2.66M – 361
2019
Q2 		$2.66M Sell
132,458
-68,619
-34% -$1.35M 0.18% 132
2019
Q1 		$4.55M Buy
+201,077
New +$4.44M 0.26% 113
2016
Q4 		– Sell
-57,400
Closed -$1.28M – 385
2016
Q3 		$1.28M Sell
57,400
-41,100
-42% -$782K 0.07% 222
2016
Q2 		$1.75M Buy
+98,500
New +$1.59M 0.09% 209
2015
Q4 		– Sell
-43,734
Closed -$886K – 301
2015
Q3 		$886K Buy
43,734
+35,616
+439% +$1.05M 0.08% 176
2015
Q2 		$269K Sell
8,118
-16,882
-68% -$462K 0.02% 215
2015
Q1 		$599K Buy
+25,000
New +$381K 0.04% 244

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

J. Goldman & Co's TVTX Position: Q1 2025 in Review

J. Goldman & Co sold out of Travere Therapeutics (TVTX) in Q1 2025, closing a stake of 181,174 shares — an estimated $3.16M sold.

J. Goldman & Co first reported a position in TVTX in Q1 2015 and held it in 9 quarters. The position peaked at $4.55M in Q1 2019. 218 funds tracked by Wall St. Rank hold TVTX as of Q1 2025.

  • J. Goldman & Co reported no remaining Travere Therapeutics position as of Q1 2025 after selling out during the quarter.
  • J. Goldman & Co sold 181,174 Travere Therapeutics shares in Q1 2025, an estimated $3.16M.
  • J. Goldman & Co first reported a position in Travere Therapeutics in Q1 2015 and held it in 9 quarters.
  • J. Goldman & Co's Travere Therapeutics position peaked at $4.55M in Q1 2019.
  • 218 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2025.

Based on J. Goldman & Co's 13F filing for Q1 2025, filed 15 May 2025.